NCT01064076

Brief Summary

This clinical study is designed to evaluate the safety and effectiveness of the subcutaneous implantable defibrillator (S-ICD) System.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
330

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2010

Typical duration for not_applicable

Geographic Reach
4 countries

33 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 4, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 8, 2010

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
4.2 years until next milestone

Results Posted

Study results publicly available

March 27, 2017

Completed
Last Updated

March 27, 2017

Status Verified

July 1, 2015

Enrollment Period

1.7 years

First QC Date

February 4, 2010

Results QC Date

November 19, 2014

Last Update Submit

February 7, 2017

Conditions

Keywords

ICD, defibrillator

Outcome Measures

Primary Outcomes (2)

  • Percentage of Participants Free of Type I Complications at 180 Days.

    Percentage of Participants Free of Type I Complications at 180 days compared to the performance goal of 79%. Type I complications are those caused by the S-ICD System.

    180 days

  • Percentage of Participants Who Pass Induced VF Conversion Test

    Percentage of participants who pass induced VF conversion test was compared to a performance goal of 88%. Definition of a success was two consecutive successful 65 joule shocks out of four attempts in the same polarity.

    Implant/Pre-Discharge

Study Arms (1)

S-ICD System

EXPERIMENTAL

This is a single arm study

Device: S-ICD System

Interventions

The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).

Also known as: SQ-RX Pulse Generator, Q-TRAK Subcutaneous Electrode, Q-GUIDE Electrode Insertion Tools, Q-TECH Programmer
S-ICD System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For patients without an existing transvenous device
  • Patient meets Class I, Class IIa or Class IIb indications/recommendations for ICD implantation per the current published guidelines at the time of enrollment
  • For patients with an existing transvenous device
  • Patient requires replacement or revision of an existing implanted transvenous ICD system
  • Age is ≥ 18 years
  • An appropriate pre-operative ECG per template provided

You may not qualify if:

  • Any condition which precludes the subject's ability to comply with the study requirements, including completion of the study.
  • Females who are pregnant or lactating and pre-menopausal women who are unwilling to use adequate birth control for the duration of the study.
  • Participation in any other investigational study without prior written consent from the study sponsor.
  • Patients with a serious medical condition and life expectancy of less than one year.
  • Patients with documented spontaneous and frequently recurring VT that is reliably terminated with anti-tachycardia pacing, unless the patient is not a candidate for a transvenous ICD system.
  • Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant.
  • Patients with unipolar pacemakers or implanted devices that revert to unipolar pacing.
  • Patients with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR) with an estimated GFR ≤ 29.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (33)

Arizona Arrhythmia Consultants

Scottsdale, Arizona, 85251, United States

Location

University of Southern California

Los Angeles, California, 90033, United States

Location

Foothill Cardiology

Pasadena, California, 91105, United States

Location

CMCA / Sequoia Hospital

Redwood City, California, 94062, United States

Location

Sharp Grossmont Hospital

San Diego, California, 92123, United States

Location

Sharp Memorial Hospital

San Diego, California, 92123, United States

Location

Pacific Heart Institute

Santa Monica, California, 90404, United States

Location

South Bay Electrophysiology

Torrance, California, 90503, United States

Location

Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

Emory University School of Medicine

Atlanta, Georgia, 30308, United States

Location

Northwestern University

Chicago, Illinois, 60611, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

Midwest Heart Foundation

Oakbrook Terrace, Illinois, 60181, United States

Location

Parkview Research Center

Fort Wayne, Indiana, 46805, United States

Location

Cooper University Hospital

Camden, New Jersey, 08103, United States

Location

Mount Sinai School of Medicine

New York, New York, 10029, United States

Location

Mid Carolina Cardiology Research

Charlotte, North Carolina, 28204, United States

Location

Forsyth Medical Center

Winston-Salem, North Carolina, 27103, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

The Ohio State University

Columbus, Ohio, 43210, United States

Location

Drexel University College of Medicine

Philadelphia, Pennsylvania, 19102, United States

Location

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29464, United States

Location

Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States

Location

Sentara Heart Hospital

Norfolk, Virginia, 23507, United States

Location

University of Washington Medical Center

Seattle, Washington, 98195, United States

Location

Heart Clinics Northwest

Spokane, Washington, 99204, United States

Location

The Vancouver Clinic

Vancouver, Washington, 98684, United States

Location

St. Antonius Ziekenhuis

Nieuwegein, 3435 CM, Netherlands

Location

Erasmus Medical Center

Rotterdam, 3015 GD, Netherlands

Location

Auckland City Hospital

Auckland, 1001, New Zealand

Location

Christchurch Hospital

Christchurch, 8140, New Zealand

Location

Papworth Hospital NHS Trust

Papworth Everard, Cambridge, CB3 8RE, United Kingdom

Location

Related Publications (3)

  • Amin AK, Gold MR, Burke MC, Knight BP, Rajjoub MR, Duffy E, Husby M, Stahl WK, Weiss R. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e006665. doi: 10.1161/CIRCEP.118.006665.

  • Burke MC, Gold MR, Knight BP, Barr CS, Theuns DAMJ, Boersma LVA, Knops RE, Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28;65(16):1605-1615. doi: 10.1016/j.jacc.2015.02.047.

  • Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, Rashtian M, Kremers M, Crozier I, Lee KL, Smith W, Burke MC. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27;128(9):944-53. doi: 10.1161/CIRCULATIONAHA.113.003042.

Related Links

MeSH Terms

Conditions

Tachycardia, Ventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Limitations and Caveats

The major limitation of this study is the lack of a control group and the relatively short follow-up time.

Results Point of Contact

Title
Michael Husby, Clinical Studies Manager
Organization
Cameron Health, Inc. a subsidiary of Boston Scientific

Study Officials

  • Michael Husby, M.S., MPH

    Cameron Health, Inc. a Subsidiary of Boston Scientific

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2010

First Posted

February 8, 2010

Study Start

January 1, 2010

Primary Completion

October 1, 2011

Study Completion

January 1, 2013

Last Updated

March 27, 2017

Results First Posted

March 27, 2017

Record last verified: 2015-07

Locations